1. GPCR/G Protein
    Neuronal Signaling
  2. 5-HT Receptor
    Dopamine Receptor

Brexpiprazole (Synonyms: OPC-34712)

Cat. No.: HY-15780 Purity: 99.38%
Handling Instructions

Brexpiprazole is a potent partial agonist at human 5-hydroxytryptamine (5-HT) 5-HT1A (Ki=0.12 nM) and dopamine D2L (Ki=0.3 nM) receptors, and an antagonist at 5-HT2A receptors (Ki=0.47 nM).

For research use only. We do not sell to patients.

Brexpiprazole Chemical Structure

Brexpiprazole Chemical Structure

CAS No. : 913611-97-9

Size Price Stock Quantity
Free Sample (0.5-1 mg)   Apply now  
10 mM * 1 mL in DMSO USD 55 In-stock
Stock in Sweden
Estimated Time of Arrival: December 31
5 mg USD 50 In-stock
Stock in Sweden
Estimated Time of Arrival: December 31
10 mg USD 70 In-stock
Stock in Sweden
Estimated Time of Arrival: December 31
50 mg USD 180 In-stock
Stock in Sweden
Estimated Time of Arrival: December 31
100 mg USD 280 In-stock
Stock in Sweden
Estimated Time of Arrival: December 31
200 mg USD 450 In-stock
Stock in the United States
Estimated Time of Arrival: December 31
500 mg USD 680 In-stock
Stock in the United States
Estimated Time of Arrival: December 31
1 g   Get quote  
5 g   Get quote  

* Please select Quantity before adding items.

  • Biological Activity

  • Protocol

  • Technical Information

  • Purity & Documentation

  • References

Description

Brexpiprazole is a potent partial agonist at human 5-hydroxytryptamine (5-HT) 5-HT1A (Ki=0.12 nM) and dopamine D2L (Ki=0.3 nM) receptors, and an antagonist at 5-HT2A receptors (Ki=0.47 nM).

IC50 & Target

Ki: 0.12 nM (5-HT1A), 0.3 nM (D2L), 0.47 nM (5-HT2A)[1]

In Vitro

Brexpiprazole, a novel serotonin-dopamine activity modulator: A role for serotonin 5-HT1A and 5-HT2A receptors. Brexpiprazole also shows potent antagonist activity at human nor adrenergic α1B (Ki=0.17 nM) and α2C receptors (Ki=0.59 nM). Brexpiprazole significantly potentiates nerve growth factor (NGF)-induced neurite outgrowth in PC12 cells, in a concentration dependent manner. Brexpiprazole (1 μM) increases the number of cells with neurites in PC12 cells. Treatment with Brexpiprazole (0.001, 0.01, 0.1 or 1.0 μM) in conjunction with NGF (2.5 ng/mL) increases the number of cells with neurites, in a concentration-dependent manner[1].

In Vivo

Brexpiprazole (0.01, 0.03, 0.1 mg/kg, p.o.) significantly ameliorates dizocilpine-induced social recognition deficits, without sedation or a reduction of exploratory behavior. In addition, Brexpiprazole alone has no effect on social recognition in untreated controlmice. By contrast, neither Risperidone(0.03 mg/kg, p.o.) nor Olanzapine (0.03 mg/kg, p.o.) alters Dizocilpine induced social recognition deficits. Finally,the effect of Brexpiprazole on Dizocilpine-induced social recognition deficits is antagonized by WAY-100,635. These results suggest that Brexpiprazole can improve Dizocilpine-induced social recognition deficits via 5-HT1A receptor activation in mice[2].

Clinical Trial
References
Preparing Stock Solutions
Concentration Volume Mass 1 mg 5 mg 10 mg
1 mM 2.3064 mL 11.5322 mL 23.0643 mL
5 mM 0.4613 mL 2.3064 mL 4.6129 mL
10 mM 0.2306 mL 1.1532 mL 2.3064 mL
Please refer to the solubility information to select the appropriate solvent.
Cell Assay
[1]

Brexpiprazole is dissolved in DMSO and stored, and then diluted with appropriate medium before use[1].

PC12 cells are cultured at 37°C, 5% CO2 in Dulbecco's modified Eagle's medium (DMEM), supplemented with 5% heat-inactivated fetal bovine serum (FBS),10% heat-inactivated horse serum, and 1% penicillin-streptomycin. Medium is changed two to three times a week. PC12 cells are plated onto 24- well tissue culture plates coated with poly-D-lysine/laminin. Cells are plated at relatively low density (0.25×104 cells/cm2) in DMEM medium containing 0.5% FBS,1% penicillin-streptomyc in Medium containing a minimal level of serum (0.5% FBS) is used. In this study, 2.5 ng/mL of NGF is used to study the potentiating effects of Brexpiprazole on neurite outgrowth. Twenty-four hours after plating, the medium is replaced with DMEM medium containing 0.5% FBS and 1% penicillin-streptomycin with NGF (2.5 ng/mL), with or without Brexpiprazole (0.001,0.01,0.1 or 1 μM), WAY-100,635 (5-HT1A receptor antagonist;10 μM), raclopride (dopamine D2 receptor antagonist;10 μM), DOI (5-HT2A receptor agonist;0.1,1 or 10 μM), M100,907 (5-HT2A receptor antagonist; 0.1, 1 or 10 μM), xestospongin C (IP3 receptor antagonist; 1 μM), 2-APB (IP3 receptor antagonist;100 μM), fluoxetine (5-HT transporter inhibitor: 1 μM), or paroxetine (5-HT transporter inhibitor: 1 μM). Four days after incubation with NGF (2.5ng/mL) with or without specified drugs, morphometric analysis is performed on digitized images of live cells taken under phase-contrast illumination, with an inverted microscope linked to a camera. Images of three fields per well are taken, with an average of 100 cells per field. Differentiated cells are counted by visual examination of the field; only cells that had at least one neurite with a length equal to the cell body diameter are counted, and are then expressed as a percentage of the total cells in the field. Counting is performed in ablinded manner[1]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Administration
[2]

Brexpiprazole is dissolved in 5% (w/v) gum Arabic[2].

Mice[2]
Male C57BL/6NCrSlc mice aged between 4 and 5 weeks old are selected as stranger mice, while animals between 8 and 10 weeks old are used for this study. All mice are housed in groups of five percage, in a room maintained at 23±2°C and 60±10% humidity, with a 12/12h light/dark cycle (lights on at 7:00 a.m.).The mice are given free access to food and water. Brexpiprazole is dissolved in 5% (w/v) gum Arabic and administered orally (p.o.), at 10 mL/kg, 1 h prior to sociability testing. The doses of antipsychotic drugs are selected based on doses that did not impact locomotion. MCE has not independently confirmed the accuracy of these methods. They are for reference only.

References
Molecular Weight

433.57

Formula

C₂₅H₂₇N₃O₂S

CAS No.

913611-97-9

SMILES

O=C1NC2=C(C=CC(OCCCCN3CCN(C4=C(C=CS5)C5=CC=C4)CC3)=C2)C=C1

Storage
Powder -20°C 3 years
  4°C 2 years
In solvent -80°C 6 months
  -20°C 1 month
Shipping

Room temperature in continental US; may vary elsewhere

Solvent & Solubility

DMSO: ≥ 48 mg/mL

* "<1 mg/mL" means slightly soluble or insoluble. "≥" means soluble, but saturation unknown.

Inquiry Online

Your information is safe with us. * Required Fields.

Product name

 

Salutation

Applicant name *

 

Email address *

Phone number *

 

Organization name *

Country or Region *

 

Requested quantity *

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
Brexpiprazole
Cat. No.:
HY-15780
Quantity: